The processing intermediate of human amylin, pro-amylin(1–48), has in vivo and in vitro bioactivity
Biophysical Chemistry · 2024
DOI: 10.1016/j.bpc.2024.107201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biophysical Chemistry, 2024. Verfasst von Giulia Mazzini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Veterinary Physiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Islet Amyloid Polypeptide, Amyloid. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NIGMS NIH HHS, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
Amylin is released by pancreatic beta-cells in response to a meal and its major soluble mature form (37 amino acid-peptide) produces its biological effects by activating amylin receptors. Amylin is derived from larger propeptides that are processed within the synthesizing beta-cell. There are suggestions that a partially processed form, pro-amylin(1-48) is also secreted. We tested the hypothesis that pro-amylin(1-48) has biological activity and that human pro-amylin(1-48) may also form toxic pre-amyloid species. Amyloid formation, the ability to cross-seed and in vitro toxicity were similar between human pro-amylin(1-48) and amylin. Human pro-amylin(1-48) was active at amylin-responsive receptors, though its potency was reduced at rat, but not human amylin receptors. Pro-amylin(1-48) was able to promote anorexia by activating neurons of the area postrema, amylin's primary site of action, indicating that amylin can tolerate significant additions at the N-terminus without losing bioactivity. Our studies help to shed light on the possible roles of pro-amylin(1-48) which may be relevant for the development of future amylin-based drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Veterinary Physiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
- Department of Pharmacology and Toxicology, University of Otago, New Zealand.
- Research Department of Structural and Molecular Biology, University College London, UK.
- Department of Chemistry, Stony Brook University, USA.
- Department of Pharmacology and Toxicology, University of Otago, New Zealand. Electronic address: debbie.hay@otago.ac.nz.
- Research Department of Structural and Molecular Biology, University College London, UK; Department of Chemistry, Stony Brook University, USA; Laufer Center for Quantitative Biology Stony Brook University, USA. Electroni…
Förderung
- Wellcome Trust
- NIGMS NIH HHS
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- National Institutes of Health
Zitieren
APA
Mazzini, G., Le Foll, C., Boyle, C. N., Garelja, M. L., Zhyvoloup, A., Miller, M. E. T., Hay, D. L., Raleigh, D. P., & Lutz, T. A. (2024). The processing intermediate of human amylin, pro-amylin(1–48), has in vivo and in vitro bioactivity. Biophysical Chemistry. https://doi.org/10.1016/j.bpc.2024.107201
Vancouver
Mazzini G, Le Foll C, Boyle CN, Garelja ML, Zhyvoloup A, Miller MET, et al. The processing intermediate of human amylin, pro-amylin(1–48), has in vivo and in vitro bioactivity. Biophysical Chemistry. 2024. doi:10.1016/j.bpc.2024.107201
BibTeX
@article{Mazzini2024,
author = {Mazzini, Giulia and Le Foll, Christelle and Boyle, Christina N and Garelja, Michael L and Zhyvoloup, Alexander and Miller, Matthew E T and Hay, Debbie L and Raleigh, Daniel P and Lutz, Thomas A},
title = {The processing intermediate of human amylin, pro-amylin(1–48), has in vivo and in vitro bioactivity},
journal = {Biophysical Chemistry},
year = {2024},
doi = {10.1016/j.bpc.2024.107201}
}
EUVIMED